BioSpace News Archive

Photo of a GLP-1 injector pen on a blue background

Legal

Siding With Novo and Lilly, Court Agrees to First Tackle ‘Cross Cutting Issues’ in GLP-1 Litigations

In agreeing with Novo Nordisk and Eli Lilly, Pennsylvania judge Karen Spencer Marston said the court should first settle questions of gastroparesis diagnosis and sufficient warnings for side effects.

August 30, 2024

·

2 min read

·

Tristan Manalac

Regulatory

J&J Poised to Challenge Argenx With Myasthenia Gravis Filing for Nipocalimab

J&J gained rights to the FcRn blocker nipocalimab when it acquired Momenta Pharmaceuticals in August 2020 for $6.5 billion.

August 30, 2024

·

2 min read

·

Tristan Manalac

Gloved hand holding a vial of mpox vaccine

Regulatory

Emergent Wins FDA Approval for Mpox Vaccine as Outbreak Rages On

Emergent BioSolutions joins Bavarian Nordic on pharma’s frontline in the fight against the ongoing mpox emergency.

August 30, 2024

·

2 min read

·

Tristan Manalac

U.S. Capitol surrounded by money and pill bottles/Taylor Tieden for BioSpace

Editorial

With Lilly’s Zepbound Price Cut and Novo’s Impending Senate Hearing, Wegovy Is in the Hot Seat

Eli Lilly this week announced plans to sell single-dose vials of its weight loss drug Zepbound directly to consumers. Novo Nordisk could adopt a similar strategy for Wegovy as its CEO is set to testify Sept. 24 before the Senate health committee.

August 30, 2024

·

3 min read

·

Greg Slabodkin

Pictured: Alnylam headquarters in Massachusetts/iS

Rare diseases

Alnylam Builds ATTR-CM Case for Vutrisiran With Strong Phase III Survival Data

Despite the added survival benefit for its drug, Alnylam still faces steep competition from Pfizer, whose ATTR-CM therapies have become established treatment options.

August 30, 2024

·

2 min read

·

Tristan Manalac